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A Metabolome-Wide Study of Dry Eye
Disease Reveals Serum Androgens
as Biomarkers
Jelle Vehof, MD, PhD,1,2,3,4 Pirro G. Hysi, MD, PhD,1,2 Christopher J. Hammond, MD, FRCOphth1,2
Purpose: To test the association between serum metabolites and dry eye disease (DED) using a hypothesis-
free metabolomics approach.
Design: Cross-sectional association study.
Participants: A total of 2819 subjects from the population-representative TwinsUK cohort in the United
Kingdom, with a mean age of 57 years (range, 17e82 years).
Methods: We tested associations between 222 known serum metabolites and DED. All subjects underwent
nontargeted metabolomic analysis of plasma samples using gas and liquid chromatography in combination with
mass spectrometry (Metabolon Inc., Durham, NC). Dry eye disease was deﬁned from the validated Short
Questionnaire for Dry Eye Syndrome (SQDES) as a previous diagnosis of DED by a clinician or “often” or
“constant” symptoms of dryness and irritation. Analyses were performed with linear mixed effect models that
included age, BMI, and sex as covariates, corrected for multiple testing.
Main Outcome Measures: Primary outcome was DED as deﬁned by the SQDES, and secondary outcomes
were symptom score of DED and a clinical diagnosis of DED.
Results: Prevalence of DED as deﬁned by the SQDES was 15.5% (n ¼ 436). A strong and metabolome-wide
signiﬁcant association with DED was found with decreased levels of the metabolites androsterone sulfate
(P ¼ 0.00030) and epiandrosterone sulfate (P ¼ 0.00036). Three other metabolites involved in androgen metabolism,
4-androsten-3beta,17beta-diol disulfate 1 and 2, and dehydroepiandrosterone sulfate, were the next most strongly
associated of the 222 metabolites, but did not reach metabolome-wide signiﬁcance. Dryness and irritation symptoms,
as opposed to a clinical diagnosis, were particularly strongly associated with decreased androgen steroid metabo-
lites, with all reaching metabolome-wide signiﬁcance (androsterone sulfate, P ¼ 0.000000029; epiandrosterone
sulfate, P ¼ 0.0000040; 4-androsten-3beta,17beta-diol disulfate 1, P ¼ 0.000016; 4-androsten-3beta,17beta-diol
disulfate 2, P¼ 0.000064; and dehydroepiandrosterone sulfate, P¼ 0.00011). Of these 5 androgens, epiandrosterone
sulfate (P ¼ 0.0076) was most associated with 2-year incidence of clinician-diagnosed DED. In addition, we found
decreased glycerophosphocholines to be associated with DED, although not at metabolome-wide signiﬁcance.
Conclusions: This hypothesis-free metabolomic approach found decreased serum androgens to be highly
associated with DED and adds important evidence to the growing body of research that links androgens to ocular
surface disease and DED. Ophthalmology 2016;-:1e7 ª 2016 by the American Academy of Ophthalmology. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Supplemental material is available at www.aaojournal.org.
Dry eye disease (DED) is a multifactorial disease and has a
complex etiology and pathophysiology.1 Dry eye disease
has been associated with a wide range of traits, including
systemic and metabolic conditions and dysfunctions, such
as vitamin A deﬁciency, lower intake of omega-3 and
omega-6 fatty acids, ovarian dysfunction, menopause, acne,
diabetes mellitus, sarcoidosis, and use of systemic medica-
tions such as antihistamines, b-blockers, antidiuretics, and
antidepressants.2 Despite the abundance of associations,
little is known about the molecular basis of DED.
Since the advent of the omics era (genomics, tran-
scriptomics, proteomics), our understanding of complex
diseases has dramatically increased. Metabolomics is a
recent addition to these techniques and has emerged as a
powerful tool in biological research. It allows the simulta-
neous analysis of hundreds of metabolites from a biological
sample and thus provides a snapshot of the metabolomic
state of a tissue.3,4 Metabolomics has the potential to iden-
tify biomarkers and functional pathways of disease and
therefore can lead to new treatment options. The power of
metabolomics as an intermediate phenotype in the analysis
of complex traits has been demonstrated in many studies,
including in ophthalmology.5
Given the many associations of DED with systemic and
metabolic traits, this study aimed to explore the relationship
between DED and serum metabolites using a hypothesis-
free or nontargeted metabolomics approach in a large
population-representative sample.
1ª 2016 by the American Academy of Ophthalmology
This is an open access article under the CC BY license
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http://dx.doi.org/10.1016/j.ophtha.2016.12.011
ISSN 0161-6420/16
Methods
Study Sample
A total of 2819 subjects from the TwinsUK cohort for whom both
metabolomic and phenotypic information were available were
included. This cohort has been ascertained from the general popu-
lation of the United Kingdom through national media campaigns.6
The TwinsUK cohort is largely female because its initial focus
was on osteoporosis and only women were recruited. However, it
has recruited men and women for the past 15 years, but there is a
strong female volunteer bias, common to all twin cohorts. Twins
from this registry have been shown to be comparable to age-
matched general population singletons for a broad variety of med-
ical and behavioral traits.7 Local ethics committee approval was
obtained for the study, and volunteers gave informed consent. The
research followed the tenets of the Declaration of Helsinki.
Dry Eye Disease Outcome Variables
Subjects from the TwinsUK cohort were invited to complete a postal
questionnaire in 2013. This included, among many questions about
systemic disease and psychologic and other traits, the Short Ques-
tionnaire for Dry Eye Syndrome (SQDES), as used and validated in the
Women’s Health Study and Physicians’ Health Study.8 The SQDES
includes 2 symptom questions: (1) “How often do your eyes feel dry
(not wet enough)?” and (2) “How often do your eyes feel irritated?”
(with the possible answers being 0 ¼ never, 1 ¼ sometimes, 2 ¼
often, or 3 ¼ constantly), and a third question about a previous
diagnosis of DED: (3) “Have you ever been diagnosed (by a
clinician) as having dry eye syndrome?” (with the possible answers
being yes or no). A subject was considered as having DED if there
was the presence of both dryness and irritation constantly or often,
and/or a report of a previous clinical diagnosis of DED. This
deﬁnition was used as the primary outcome variable of our
metabolomics analysis. Second, we analyzed symptoms (using the
sum score of the 2 symptom questions of SQDES) and the presence
of a clinical diagnosis separately. Subsequently, we checked
signiﬁcant metabolites for an association with incident cases of DED
as deﬁned by a new clinical diagnosis between 2011 and 2013
compared with controls without a clinical diagnosis of DED in both
2011 and 2013. Data on the SQDES were not collected in 2011.
Metabolomics
Nontargeted ultrahigh-performance liquid chromatography and
mass spectrometry were performed on fasting plasma samples of
TwinsUK participants using the Metabolon platform (Metabolon,
Inc., Durham, NC), as described previously in more detail.9 The
metabolomic data set contained acylcarnitines, amino acids, car-
bohydrates, glycerophospholipids, lipids, nucleotides, peptides,
sphingomyelins, steroids, vitamins, and xenobiotics.
Statistical Association Analyses
Raw metabolomic data were median normalized for daily ﬂuctu-
ations of the method. Subsequently, because the data were not
normally distributed, they were inverse normalized. To avoid bias
of the parameter estimates arising from small sample size, metab-
olites determined in fewer than 2000 subjects were excluded. This
led to a total of 341 serum metabolites determined, of which 222
were fully characterized metabolites at the time of analysis, and
these were examined for an association with DED.
We used a linear mixed effect analysis to perform analyses of
the relationship between DED and single metabolites, adjusting for
age at the time when the questionnaire was administered, as well as
age at venipuncture, body mass index (BMI), and sex (LME4
package in R). Additional ﬁxed effects terms included family twin
relatedness, batch, and zygosity. Ordinal variables, such as the
dryness and irritation symptoms sum score, were analyzed as
quantitative; for binary outcomes, such as a clinical diagnosis of
DED, the switch “binomial” in the R LME4 package was used.
P values were calculated with the analysis of variance function by
likelihood ratio test of the full model including the metabolite
versus the null model excluding the metabolite.
Because of the correlations between metabolites, principal
component analysis was used to determine the number of principal
components that were linearly uncorrelated. A Bonferroni correc-
tion using the number of principal components with an eigenvalue
higher than 1 was used to correct for multiple testing. This led us to
consider a P value of 0.0012 (0.05 divided by 43 principal com-
ponents) or below statistically signiﬁcant in the main analyses.
Results
The majority of 2819 subjects in this study were female (n ¼ 2652,
94.1%). The subjects had a mean age of 57 years (standard devi-
ation [SD], 12.0 years), ranging from 17 to 82 years. The BMI
ranged from 16 to 53 kg/m2, with a mean BMI of 26.1 kg/m2
(SD, 4.7 kg/m2).
Prevalence of DED, as deﬁned by the SQDES, was 15.5%
(n ¼ 436). A total of 373 subjects (13.2%) had a clinical diagnosis
of dry eye, and 183 subjects (6.5%) had both dryness and irritation
symptoms often or constantly. Mean dryness score was 0.51 (SD,
0.70), and mean irritation score was 0.78 (SD, 0.64). In the 2-year
period between 2011 and 2013, there were 120 incident cases
(5.1%) with a clinical diagnosis of DED among 2374 subjects who
completed the questionnaires in both years.
Of the 222 metabolites, 2 androgens reached a metabolome-
wide signiﬁcant association with DED, as deﬁned by the
SQDES. These metabolites were androsterone sulfate (P ¼
0.00030) and epiandrosterone sulfate (P ¼ 0.00036). The 15 most-
associated metabolites are listed in Table 1. In total, 5 androgens
were included in the metabolomics screen, and they were the
most associated metabolites. The next 10 strongest associations
included 4 glycerophosphocholines, although not at metabolome-
wide statistical signiﬁcance.
By subdividing our metabolomic analysis into symptoms and a
clinical diagnosis separately, stronger associations were found with
symptoms (Table 2), showing highly, metabolome-wide, signiﬁcant
associations for all the 5 androgenmetabolites. Similar metabolome-
wide signiﬁcant associations as the primary analysis were
found analyzing a clinical diagnosis of DED (Table 3), with
epiandrosterone sulfate (P ¼ 0.00029) and androsterone sulfate
(P ¼ 0.00110) most associated. A complete overview of all
association results of the 222 metabolites with the 3 outcome
measures can be found in Supplemental Tables S1 to S3
(available at www.aaojournal.org).
The androgen metabolites were subsequently tested for an
association with incidence of DED, and epiandrosterone sulfate
(P ¼ 0.0076) appeared to be the most strongly associated, with the
other 4 androgens showing nominal signiﬁcance levels, before
multiple testing correction: 4-androsten-3beta,17beta-diol disulfate
1, P ¼ 0.046; androsterone sulfate, P ¼ 0.055; dehydroepian-
drosterone sulfate, P ¼ 0.063; and 4-androsten-3beta,17beta-diol
disulfate 2, P ¼ 0.085. These results suggest that epiandrosterone
sulfate might be the most potent biomarker of DED.
As expected,10 androgens declined with age in women
(epiandrosterone sulfate b ¼ 0.019, androsterone sulfate b ¼
0.020, DHEA-S b ¼ 0.032, 4-androsten-3beta,17beta-diol
disulfate 1 b ¼ 0.021, 4-androsten-3beta,17beta-diol disulfate 2
b ¼ 0.026, all P < 0.001). In men this decline with age was
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less strong for some of the androgens (epiandrosterone sulfate b ¼
0.008, P ¼ 0.10; androsterone sulfate b ¼ 0.018, P ¼ 0.002;
DHEA-S b ¼ 0.033, P < 0.001, 4-androsten-3beta,17beta-diol
disulfate 1 b ¼ 0.014, P ¼ 0.02, 4-androsten-3beta,17beta-diol
disulfate 2 b ¼ 0.012, P ¼ 0.03). As the regression
coefﬁcients of the heavily transformed metabolites do not give
easy interpretable information, Figure 1 gives an idea of the
strength of the relationship between serum androgens (divided in
3 groups, based on their androgen levels, corrected for age,
gender, and BMI) and prevalence of DED as deﬁned by the
SQDES (Fig 1A) and mean symptoms score (Fig 1B).
Discussion
In this hypothesis-free study, we have shown strong asso-
ciations of DED with all 5 androgens included in this screen
of 222 known metabolites. The most signiﬁcant associations
with androgens were found with symptoms of DED,
compared with a clinical diagnosis of DED.
Androgens, together with estrogens and progestogens,
are the 3 sex steroids. They are released into the blood-
stream after production in the testes and to a lesser degree in
Table 1. Fifteen Strongest Associations of a Serum Metabolomics Study of Dry Eye Disease, as Deﬁned by the Short Questionnaire of Dry
Eye Diseasey
Metabolite Pathway Super-pathway P Value b
Androsterone sulfate Sterol/steroid Lipid 0.00030* 0.20
Epiandrosterone sulfate Sterol/steroid Lipid 0.00036* 0.20
4-Androsten-3beta,17beta-diol disulfate 1 Sterol/steroid Lipid 0.0023 0.19
DHEA-S Sterol/steroid Lipid 0.0023 0.18
4-Androsten-3beta,17beta-diol disulfate 2 Sterol/steroid Lipid 0.0077 0.17
Theophylline Xanthine metabolism Xenobiotics 0.016 0.14
N1-methyladenosine Purine metabolism, adenine containing Nucleotide 0.016 0.13
1-Palmitoylglycerophosphocholine Lysolipid Lipid 0.022 0.12
Caffeine Xanthine metabolism Xenobiotics 0.034 0.12
1,7-Dimethylurate Xanthine metabolism Xenobiotics 0.037 0.12
Serine Glycine, serine, and threonine metabolism Amino acid 0.046 0.11
2-Palmitoylglycerophosphocholine Lysolipid Lipid 0.050 0.10
2-Linoleoylglycerophosphocholine Lysolipid Lipid 0.062 0.11
1-Stearoylglycerophosphocholine Lysolipid Lipid 0.063 0.10
Alanine Alanine and aspartate metabolism Amino acid 0.078 0.10
DHEA-S ¼ dehydroepiandrosterone sulfate.
*Metabolome-wide signiﬁcant association (P < 0.0012).
yA subject was considered as having dry eye disease (DED) if both dryness and irritation symptoms were present constantly or often, and/or a report of a
previous clinical diagnosis of DED.
Table 2. Fifteen Strongest Associations of a Serum Metabolomics Study with Outcome Variable Dryness and Irritation Symptoms
Metabolite Pathway Super-pathway P Value b
4-Androsten-3beta,17beta-diol disulfate 2 Sterol/steroid Lipid 2.9E-08* 0.16
Androsterone sulfate Sterol/steroid Lipid 0.0000040* 0.11
Epiandrosterone sulfate Sterol/steroid Lipid 0.000016* 0.11
4-Androsten-3beta,17beta-diol disulfate 1 Sterol/steroid Lipid 0.000064* 0.11
DHEA-S Sterol/steroid Lipid 0.00011* 0.10
3-(4-Hydroxyphenyl)lactate Phenylalanine and tyrosine metabolism Amino acid 0.0021 0.07
Glycerol Glycerolipid metabolism Lipid 0.00394 0.07
Erythronate Amino sugars metabolism Carbohydrate 0.025 0.05
Heptanoate (7:0) Medium-chain fatty acid Lipid 0.027 0.05
Allantoin Purine metabolism, urate metabolism Nucleotide 0.028 0.06
1,7-Dimethylurate Xanthine metabolism Xenobiotics 0.031 0.06
Linolenate (a or g [18:3n3 or 6]) Essential fatty acid Lipid 0.031 0.05
1-Oleoylglycerophosphoethanolamine Lysolipid Lipid 0.036 0.05
Caproate (6:0) Medium-chain fatty acid Lipid 0.042 0.05
Linoleate (18:2n6) Essential fatty acid Lipid 0.043 0.05
DHEA-S ¼ dehydroepiandrosterone sulfate.
*Metabolome-wide signiﬁcant association (P < 0.0012).
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the ovaries and adrenal glands. In addition, sex steroids are
produced by intracrine conversion of steroid precursors in
other body tissues, such as body fat and skin. The biosyn-
thetic pathway and interplay between androgens are
complicated. Dehydroepiandrosterone (DHEA) is the pre-
cursor of androgens (and estrogens) and leads via enzymes
such as 5a-reductase to epiandrosterone, androsterone,
testosterone, and other steroids; 4-androstene-3beta,17beta-
diol disulfate 1 and 2 also are known as androstenediols and
are intermediates in the synthesis of testosterone from
DHEA. Dehydroepiandrosterone sulfate (DHEA-S) is a
metabolite of DHEA, but also can be back-converted to
DHEA.11 Testosterone and di-hydro testosterone have the
highest potency as androgens, and DHEA, epiandrosterone,
and androsterone are relatively weak androgens. The an-
drogens in our metabolomics screen are, not surprisingly,
highly correlated, with correlations among the 5 androgens
ranging from 0.55 to 0.94 (all P < 0.001).
This study is the ﬁrst hypothesis-free study that links
androgens to DED, but not the ﬁrst overall study that links
them. Androgen levels have been shown to inﬂuence the
structure and function of the lacrimal and meibomian
glands, with reduced androgens levels leading to reduced
tear volume, reduced tear ﬁlm stability by decreased quality
and quantity of meibomian gland lipids, decreased tear
turnover rate, and hyperosmolarity. In addition, androgens
have been shown to have a direct effect on the tissues of the
ocular surface, such as the conjunctiva, leading to altered
mucin production.12e16 Also, women with Sjögren’s disease
have been shown to be androgen deﬁcient.17 Although our
metabolomic study is not testing causality, on the basis of
all these studies, it is likely that reduced serum androgen
levels are causative of DED. The exact relationship
between serum androgens and tear ﬁlm and ocular surface
androgens remains to be elucidated. Glucuronide and
sulfate androgen metabolites in the serum, as measured by
our metabolomics screen, have been shown to be the most
valid and possibly only reliable estimate of the total
androgen pool including the intracrine production in
peripheral tissues,10,18 which is most likely the most
important source in ocular surface tissues.
Given the results in this study, androgens might be a
potential pathway for the treatment of DED. Bizzarro et al19
showed that 3 patients with DED and Sjögren syndrome
had signiﬁcantly increased Schirmer tests and decreased
Bijsterveld scores after 60 days of oral testosterone
undecanoate treatment, while no differences were found with
respect to basal values after 60 days of placebo treatment.
However, a recent, somewhat bigger, randomized, placebo-
controlled pilot study on dry eye in 40 postmenopausal
women did not show a beneﬁcial effect of either transdermal
testosterone, estrogen or both testosterone and estrogen on
dry eye symptoms as compared to placebo.20 It did show a
positive effect on tear secretion in the group with both
testosterone cream and estrogen gel. In addition, in the
testosterone group changes in serum 3-a-androstanediol-
glucoronide, an androgen metabolite, were strongly
positively associated with a change in tear breakup time
(r ¼ 0.83, P ¼ 0.01), supporting our ﬁnding of an
association between serum androgen metabolites and dry
eye. In addition to these small randomized clinical trials
there are also several case-series and case-reports reported
that show a potential beneﬁt of androgen treatment in dry
eye disease. Among them, Nanavaty et al21 published a case
series of 14 women with evaporative dry eye that
signiﬁcantly improved after use of transdermal androgen
patches. Symptoms, measured by the Ocular Surface
Disease Index, and signs, measured by tear breakup time
and the Schirmer test, both improved after 3 weeks of
androgen patching.21 Another case report reported
improvement in DED signs and symptoms in a patient who
received testosterone cream applied to the eyelids for 3
months.22 Other retrospective case studies reported
improvement in DED after combined androgen and estrogen
systemic therapy23 and worsening of DED parameters after
antiandrogen therapy,24 but other studies failed to prove
improvement of DED parameters after systemic DHEA
supplementation in patients with Sjögren’s syndrome.25,26
Table 3. Fifteen Strongest Associations of a Serum Metabolomics Study with Outcome Variable a Clinical Diagnosis of Dry Eye Disease
Metabolite Pathway Super-pathway P Value b
Epiandrosterone sulfate Sterol/steroid Lipid 0.00029* 0.22
Androsterone sulfate Sterol/steroid Lipid 0.0011* 0.20
DHEA-S Sterol/steroid Lipid 0.0041 0.18
4-Androsten-3beta,17beta-diol disulfate 1 Sterol/steroid Lipid 0.014 0.17
N1-methyladenosine Purine metabolism, adenine containing Nucleotide 0.017 0.14
Serine Glycine, serine, and threonine metabolism Amino acid 0.026 0.13
1-Palmitoylglycerophosphocholine Lysolipid Lipid 0.030 0.12
4-Androsten-3beta,17beta-diol disulfate 2 Sterol/steroid Lipid 0.034 0.14
5-Dodecenoate (12:1n7) Medium-chain fatty acid Lipid 0.048 0.12
Xanthine Purine metabolism, (hypo)xanthine/inosine containing Nucleotide 0.051 0.13
Theophylline Xanthine metabolism Xenobiotics 0.051 0.12
Myristoleate (14:1n5) Long-chain fatty acid Lipid 0.054 0.12
Indolelactate Tryptophan metabolism Amino acid 0.057 0.11
Myristate (14:0) Long-chain fatty acid Lipid 0.059 0.12
1-Stearoylglycerophosphocholine Lysolipid Lipid 0.063 0.11
DHEA-S ¼ dehydroepiandrosterone sulfate.
*Metabolome-wide signiﬁcant association (P < 0.0012).
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Larger placebo-controlled studies are needed to further eluci-
date the possible effects of androgen treatment and to inves-
tigate which treatment modality is most useful and which
patient groups are most likely to beneﬁt.
A metabolomic approach to DED has been used before in a
few settings, albeit always with a limited sample size and a
small range of metabolites, but to our knowledge never using
serum samples in a large population-based study. Galbis-
Estrada et al27 performed a case-control study involving 90
participants with no, mild, or moderate DED and including 42
tear metabolites. The authors found a differential tear metab-
olomics proﬁle among the 3 groups that decreased after sup-
plementation with antioxidants and omega 3 fatty acids.28 The
authors concluded that supplementation leads to restored
normal tear proﬁles. No steroid metabolites were included in
that study. A metabolomics analysis of human conjunctival
epithelial cells in response to hyperosmotic stress found that
levels of 21 metabolites signiﬁcantly changed under
hyperosmotic stress29; glycerophosphocholine increased most
under hyperosmotic stress, and the authors concluded that
this metabolite may act as an important osmoprotectant. Of
note, in our primary analysis (Table 1), 4 of the 15 strongest
metabolomic associations were glycerophosphocholines, with
decreased levels associated with DED. The metabolite
1-palmitoylglycerophosphocholine also showed a signiﬁcant
association with incidence of a clinical diagnosis of DED
(P ¼ 0.020). So, this metabolite may act as a serum
biomarker for dry eye. Our ﬁndings extend to these tear
metabolomics studies showing that DED is associated not
only with altered local metabolites but also with altered
systemic metabolites. Our group previously showed that
DED shares genetic factors with chronic widespread
musculoskeletal pain.30 Of note, epiandrosterone sulfate
levels were found to be inversely associated with chronic
widespread musculoskeletal pain in a metabolomics study.31
Given these ﬁndings, one might speculate that the androgen
pathway is a common mechanism to both these conditions.
More studies are needed to investigate this in further detail.
Study Limitations
First, despite the large sample size, this study was conducted
on a single sample of volunteer twins and has not been
independently replicated. Second, the majority of our
Figure 1. A, Prevalence of dry eye disease per serum androgen tertile. A subject was considered as having dry eye disease if there was presence of both
dryness and irritation symptoms either constantly or often, and/or a report of a previous clinical diagnosis of dry eye disease. Serum androgen levels were
corrected for age, body mass index (BMI) and gender. Error bars represent 95% conﬁdence intervals. B, Dry eye symptoms score per serum androgen tertile.
Dry eye symptoms score was the sum of 2 questions investigating the frequency of dryness symptoms and of irritation symptoms (both scored from 0 to 3).
Serum androgen level were corrected for age, BMI and gender. Error bars represent 95% conﬁdence intervals.
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subjects were female, potentially advantageous in a trait
such as DED, which is more common in women, but the
results may be less generalizable to men. Although our
study included only 167 men, the direction of effect was the
same for the androgen metabolites but seemed less strong.
Deﬁning exact menopausal status is difﬁcult in population
studies of this age range, but the effects were broadly similar
in women below 55 years and above 55 years of age (data
not shown). Third, the variable symptom sum score is
semiquantitative, and analyzing it using regression-based
techniques is imperfect given the assumptions they make.
The advantages of our study include the large sample size
compared with all previous studies in this ﬁeld, the non-
targeted nature of the metabolites measured, and the sig-
niﬁcant associations with clinical end points, corrected for
multiple testing.
In summary, this hypothesis-free metabolomic study
found highly signiﬁcant associations between decreased
androgen levels and DED, especially symptoms. Andro-
gens, and possibly epiandrosterone the most, may act as a
biomarker for dry eye, and we encourage more clinical trials
to investigate whether topical or systemic androgen therapy
is useful in DED. In addition, this study added evidence to
the recent ﬁnding that glycerophosphocholines may be
important as an osmoprotectant in DED.
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